PDF herunterladen
Fortschr Neurol Psychiatr 2011; 79(1): 21-25
DOI: 10.1055/s-0029-1245885
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Symptomvielfalt nach Konsum der Droge Gamma-Hydroxybuttersäure (GHB)

Variety of Symptoms after Drug Use of Gamma-Hydroxybutyric Acid (GHB)N. Galldiks1 , I. Kadow2 , A. Bechdolf2 , G. R. Fink1 , J. Klosterkötter2 , J. Kuhn2
  • 1Klinik und Poliklinik für Neurologie, Uniklinik Köln
  • 2Klinik und Poliklinik für Psychiatrie, Uniklinik Köln
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
09. Dezember 2010 (online)

    Lizenzen und Reprints

Zusammenfassung

Der Konsum von Gamma-Hydroxybuttersäure (GHB, „flüssiges XTC”) sowie der legalen Vorstufen Gamma-Butyrolacton und 1,4-Butandiol gewinnt in Deutschland immer mehr an Bedeutung. Aufgrund der weiten Verbreitung dieser Droge und seiner Vorstufen werden Kliniker derzeit vor allem vermehrt mit GHB-Intoxikationen konfrontiert. Die Wirkungen dieser Substanzen können bei Überdosierung Symptomen beispielsweise einer Intoxikation mit Alkohol und/oder Benzodiazepinen ähneln. Neben Symptomen der Intoxikation können aber auch GHB-Entzugssymptome erhebliche differenzialdiagnostische Schwierigkeiten bereiten. Dabei können neben vegetativen Entzugssyndromen insbesondere auch psychotische Symptome auftreten. In dieser Übersicht werden Geschichte, Pharmakodynamik und -kinetik sowie die relevanten Symptome von Intoxikation und Entzug auf neurologischem und psychiatrischem Fachgebiet dargestellt.

Abstract

Gamma-Hydroxybutyric acid (GHB, ”liquid ecstasy”) and its legal prodrugs gamma-butyrolactone and 1,4-butanediol are gaining importance as recreational drugs in Germany. Because of the wide availability of GHB and its prodrugs physicians are increasingly being confronted with cases of intoxication. The effect of GHB intoxication is comparable with those of alcohol and/or benzodiazepines. Likewise, symptoms of withdrawal may occur. In this review, we summarise current data regarding the history, pharmacodynamics and pharmacokinetics of the drug as well as the relevant symptoms of intoxication or withdrawal as they pertain to neurology and psychiatry.

Schlüsselwörter

GHB-Entzugssyndrom - GHB-Intoxikation - „flüssiges XTC” - GHB-Abhängigkeit

Keywords

symptoms of withdrawal - GHB intoxikation - ”liquid ecstasy” - dependency on GHB

Literatur

  • 1 Andresen H, Stimpfl T, Sprys N et al. Liquid ecstasy – a significant drug problem.  Dtsch Arztebl Int. 2008;  105 599-603
    Google Scholar
  • 2 European Monitoring Centre for Drugs and Drug Addiction .EMCDDA Thematic Papers – GHB and its precursor GBL: an emerging trend case study. http://www.emcdda.europa.eu/html.cfm/index7079EN.html
    Google Scholar
  • 3 Bessman S P, Fishbein W N. Gamma-Hydroxybutyrate, a Normal Brain Metabolite.  Nature. 1963;  200 1207-1208
    Google Scholar
  • 4 Anderson R A, Ritzmann R F, Tabakoff B. Formation of gamma-hydroxybutyrate in brain.  J Neurochem. 1977;  28 633-639
    Google Scholar
  • 5 Cash C D. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent.  Neurosci Biobehav Rev. 1994;  18 291-304
    Google Scholar
  • 6 Laborit H. Sodium 4-Hydroxybutyrate.  Int J Neuropharmacol. 1964;  3 433-451
    Google Scholar
  • 7 Takahara J, Yunoki S, Yakushiji W et al. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans.  J Clin Endocrinol Metab. 1977;  44 1014-1017
    Google Scholar
  • 8 Gobaille S, Schleef C, Hechler V et al. Gamma-hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain.  Life Sci. 2002;  70 2101-2112
    Google Scholar
  • 9 Nightingale S L. From the Food and Drug Administration.  JAMA. 1991;  265 1802
    Google Scholar
  • 10 ElSohly M A, Salamone S J. Prevalence of drugs used in cases of alleged sexual assault.  J Anal Toxicol. 1999;  23 141-146
    Google Scholar
  • 11 Miotto K, Darakjian J, Basch J et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal.  Am J Addict. 2001;  10 232-241
    Google Scholar
  • 12 Entholzner E, Mielke L, Pichlmeier R et al. EEG changes during sedation with gamma-hydroxybutyric acid.  Anaesthesist. 1995;  44 345-350
    Google Scholar
  • 13 Gallimberti L, Canton G, Gentile N et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.  Lancet. 1989;  2 787-789
    Google Scholar
  • 14 Leone M A, Vigna-Taglianti F, Avanzi G et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.  Cochrane Database Syst Rev. 2010;  2 CD006266
    Google Scholar
  • 15 Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy.  Can J Neurol Sci. 1980;  7 23-31
    Google Scholar
  • 16 Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate.  Can J Neurol Sci. 1979;  6 1-6
    Google Scholar
  • 17 Madea B, Musshoff F. Knock-out drugs: their prevalence, modes of action, and means of detection.  Dtsch Arztebl Int. 2009;  106 341-347
    Google Scholar
  • 18 Tabakoff B, Wartburg J P. Separation of aldehyde reductases and alcohol dehydrogenase from brain by affinity chromatography: metabolism of succinic semialdehyde and ethanol.  Biochem Biophys Res Commun. 1975;  63 957-966
    Google Scholar
  • 19 Gonzalez von A, Nutt D J. Gamma hydroxy butyrate abuse and dependency.  J Psychopharmacol. 2005;  19 195-204
    Google Scholar
  • 20 Carai M A, Colombo G, Brunetti G et al. Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid.  Eur J Pharmacol. 2001;  428 315-321
    Google Scholar
  • 21 Drasbek K R, Christensen J, Jensen K. Gamma-hydroxybutyrate – a drug of abuse.  Acta Neurol Scand. 2006;  114 145-156
    Google Scholar
  • 22 Feigenbaum J J, Howard S G. Does gamma-hydroxybutyrate inhibit or stimulate central dopamine release?.  Int J Neurosci. 1996;  88 53-69
    Google Scholar
  • 23 Aktories, Förstermann, Hofmann et al. Allgemeine und spezielle Pharmakologie und Toxikologie. Urban & Fischer Verlag; 2009 10. Aufl
    Google Scholar
  • 24 Stein M. Stellungnahme zur nicht geringen Menge von Gamma-Hydroxybuttersäure.  Toxichem & Krimtech. 2003;  70 87-92
    Google Scholar
  • 25 Liechti M E, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre.  Swiss Med Wkly. 2004;  134 534-537
    Google Scholar
  • 26 Harrington R D, Woodward J A, Hooton T M et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate.  Arch Intern Med. 1999;  159 2221-2224
    Google Scholar
  • 27 Templeton A, Vonesch H. Intoxikation mit GHB („liquid ecstasy”).  Schweiz Med Forum. 2005;  5 115-116
    Google Scholar
  • 28 Goodwin A K, Griffiths R R, Brown P R et al. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.  Psychopharmacology. 2006;  189 71-82
    Google Scholar
  • 29 Felmlee M A, Wang Q, Cui D et al. Mechanistic Toxicokinetic Model for gamma-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potenzial Therapeutic Strategy.  AAPS J. 2010;  12 407-416
    Google Scholar
  • 30 Mazarr-Proo S, Kerrigan S. Distribution of GHB in tissues and fluids following a fatal overdose.  J Anal Toxicol. 2005;  29 398-400
    Google Scholar
  • 31 Zvosec D L, Smith S W, Porrata T et al. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma.  Am J Emerg Med.. 2010 Apr 26. [Epub ahead of Print]
    Google Scholar
  • 32 Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007.  Acta Anaesthesiol Scand. 2010;  54 987-992
    Google Scholar
  • 33 AWMF Online Leitlinie Medikamentenabhängigkeit. http://www.uni-duesseldorf.de/AWMF/ll/076-009.htm
    Google Scholar
  • 34 McDonough M, Kennedy N, Glasper A et al. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.  Drug Alcohol Depend. 2004;  75 3-9
    Google Scholar
  • 35 Bania T C, Ashar T, Press G et al. Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model.  Acad Emerg Med. 2003;  10 697-704
    Google Scholar
  • 36 Wojtowicz J M, Yarema M C, Wax P M. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.  CJEM. 2008;  10 69-74
    Google Scholar
  • 37 Constantinides P, Vincent P. Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report.  Cases J. 2009;  2 7520
    Google Scholar
  • 38 Galloway G P, Frederick S L, Staggers Jr F E et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.  Addiction. 1997;  92 89-96
    Google Scholar
  • 39 Chin R L. A case of severe withdrawal from gamma-hydroxybutyrate.  Ann Emerg Med. 2001;  37 551-552
    Google Scholar
  • 40 Craig K, Gomez H F, McManus J L et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review.  J Emerg Med. 2000;  18 65-70
    Google Scholar

Dr. Norbert Galldiks

Klinik und Poliklinik für Neurologie, Uniklinik Köln

Kerpener Str. 62

50924 Köln

eMail: norbert.galldiks@uk-koeln.de

      >